ATC Group: N05BA08 Bromazepam

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of N05BA08 in the ATC hierarchy

Level Code Title
1 N Nervous system
2 N05 Psycholeptics
3 N05B Anxiolytics
4 N05BA Benzodiazepine derivatives
5 N05BA08 Bromazepam

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
ORAL - Oral 10 mg

Active ingredients in N05BA08

Active Ingredient Description
Bromazepam

Bromazepam is a pyridylbenzodiazepine compound with anxiolytic properties.

Related product monographs

Title Information Source Document Type  
AKAMON Tablet Υπουργείο Υγείας (CY) MPI, EU: SmPC
LEXOTAN Tablet Health Products Regulatory Authority (IE) MPI, EU: SmPC

Medicines in this ATC group

Australia (AU)

Austria (AT)

Ecuador (EC)

Estonia (EE)

France (FR)

Germany (DE)

Hong Kong (HK)

Ireland (IE)

Japan (JP)

Lithuania (LT)

Mexico (MX)

Nigeria (NG)

Poland (PL)

Singapore (SG)

South Africa (ZA)

Spain (ES)

Tunisia (TN)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.